| YANG Jing-kui,HUO Xiao-dong,YAN Wei-liang,ZHENG Guang-jun,CHAI Shu-de,MENG Na,YANG Rui-jie,WANG Jun-jie.CT-guided 125I seed implantation in the treatment of malignant pulmonary metastases[J].Chinese Journal of Radiological Medicine and Protection,2013,33(5):505-507 |
| CT-guided 125I seed implantation in the treatment of malignant pulmonary metastases |
| Received:December 29, 2012 |
| DOI：10.3760/cma.j.issn.0254-5098.2013.05.012 |
| KeyWords:Pulmonary metastases Radioactive 125I seeds Surgical resection |
| FundProject: |
| Author Name | Affiliation | E-mail | | YANG Jing-kui | Department of Thoracic Surgery, Second Hospital of Tianjin Medical University, Tianjin 300211, China | | | HUO Xiao-dong | Department of Thoracic Surgery, Second Hospital of Tianjin Medical University, Tianjin 300211, China | xxwtj@sina.com | | YAN Wei-liang | Department of Thoracic Surgery, Second Hospital of Tianjin Medical University, Tianjin 300211, China | | | ZHENG Guang-jun | Department of Thoracic Surgery, Second Hospital of Tianjin Medical University, Tianjin 300211, China | | | CHAI Shu-de | Department of Thoracic Surgery, Second Hospital of Tianjin Medical University, Tianjin 300211, China | | | MENG Na | 北京大学第三医院肿瘤治疗中心放疗科 | | | YANG Rui-jie | 北京大学第三医院肿瘤治疗中心放疗科 | | | WANG Jun-jie | 北京大学第三医院肿瘤治疗中心放疗科 | |
|
| Hits: 4139 |
| Download times: 2342 |
| Abstract:: |
| Objective To evaluate the clinical outcomes and the prognostic factors in patients with pulmonary metastases treated with CT-guided radioactive 125I seed implantation (CTRISI). Methods A total of 50 patients were treated with implantation of 125I radioactive seeds under computed tomography (CT) guidance or combined with surgical resection. There were 10 (20%) patients with colorectal cancer, 8 (16%) patients with malignant fibrous histiocytoma, 5 (10%) patients with sarcoma, 22(44%) patients with other cancer, respectively. CTRISI was the only treatment in 45 patients (90%) and combined with surgical resection in 5 (10%). The local control rate, the survival rate and the factor associated with overall survival were evaluated. Results The D90% was(112.3±12.2)Gy,the V90 was 91.3%±8.2%,and the postoperative matched peripheral dose (MPD) was 106.2 Gy. The local control rate for 1-, 2-, 3-, 4-, 5-year were 95.8%, 86.5%, 56.6%, 42.4%, 31.1%, respectively. At a mean follow-up of 26 months (7-74 months), 6 patients were alive. The median survival time was 27.1 months. The survival rate for 1-,2-,3-,4-,5-year were 83.4%,52.3%,38.7%,20.3%,13.7%, respectively. Lesion size≤4 cm or>4 cm was an important prognostic factor associated with overall survival(χ2=4.621,P<0.05) and disease-free survival(χ2=7.548,P<0.05). Conclusions CTRISI is safe in these patients with pulmonary metastases, with promising results. Surgical resection remains the standard for resectable patients, while CTRISI alone or combined with surgery might offer an alternative in selected patients. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
